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Abstract 
 
In response to the stress of infection, Mycobacterium tuberculosis (Mtb) reprograms its 
metabolism to accommodate nutrient and energetic demands in a changing environment. 
Pyruvate kinase (PYK) is an essential glycolytic enzyme in the phosphoenolpyruvate (PEP)-
pyruvate-oxaloacetate node that is a central switch point for carbon flux distribution. Here we 
show that the competitive binding of pentose monophosphate inhibitors or the activator 
glucose 6-phosphate (G6P) to MtbPYK tightly regulates the metabolic flux. Intriguingly, 
pentose monophosphates were found to share the same binding site with G6P. The 
determination of a crystal structure of MtbPYK with bound ribose 5-phosphate (R5P), 
combined with biochemical analyses and molecular dynamic simulations, revealed that the 
allosteric inhibitor pentose monophosphate increases PYK structural dynamics, weakens the 
structural network communication, and impairs substrate binding. G6P on the other hand, 
primes and activates the tetramer by decreasing protein flexibility and strengthening allosteric 
coupling. Therefore, we propose that MtbPYK uses the conformational dynamics to control 
the opposite allosteric regulation. Importantly, metabolome profiling in mycobacteria reveals 
a significant increase in the levels of pentose monophosphate during hypoxia, which provides 
insights into how PYK uses dynamics of the tetramer as a competitive allosteric mechanism 
to retard glycolysis and facilitate metabolic reprogramming toward the pentose-phosphate 
pathway for achieving redox balance and an anticipatory metabolic response in Mtb. 
 
Keywords: allosteric regulation; structural dynamics; metabolic reprogramming; stress 
response 
Abbreviations: CCM, central carbon metabolism; F6P, fructose 6-phosphate; G3P, 
glyceraldehyde 3-phosphate; G6P, glucose 6-phosphate; MtbPYK, Mycobacterium 
tuberculosis pyruvate kinase; OX, oxalate; PEP, phosphoenolpyruvate; R5P, ribose 5-
phosphate; X5P, xylulose 5-phosphate; 5RP, ribulose 5-phosphate 
Introduction 
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Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis (TB), replicates, evolves 
and persists within human hosts by successfully adapting to the environmental challenges 
imposed by the human immune system[1-4]. Following phagocytosis by macrophages, Mtb 
mainly relies on lipids as carbon and energy sources. However, co-metabolism and metabolic 
plasticity of central carbon metabolism (CCM), which includes glycolysis, gluconeogenesis, 
the pentose-phosphate pathway (PPP), the tricarboxylic acid (TCA) cycle, and the glyoxylate 
shunt, are also essential in Mtb physiology and pathogenicity and help fine-tune carbon and 
energy metabolism[5-8]. Recently, Eoh et al. reported that the adaptation of Mtb to hypoxia 
was accompanied by the accumulation of glycolytic and PPP intermediates, as an anticipatory 
metabolic regulatory response required for cell cycle re-entry[9,10]. Currently, transcriptional, 
epitranscriptional, and metabolic responses have been extensively characterised to 
investigate the regulatory adaptation of Mtb to stress[4,7,9,11]. The allosteric regulation of a 
metabolic enzyme has recently received increasing attention as a key mechanism governing 
rapid cellular response and adaptation[6,8,12]. Here we describe how the glycolytic enzyme 
pyruvate kinase (PYK) in Mtb tightly governs the phosphoenolpyruvate (PEP)-pyruvate-
oxaloacetate node by a conformational dynamics-driven mechanism, that not only activates 
but also inhibits activity using a single remote allosteric site. 
 Recently, we showed that glucose 6-phosphate (G6P) allosterically activates MtbPYK 
and binds at a previously unknown site in the C-domain adjacent to the canonical site for 
AMP[12] (Fig. S1). This newly discovered allosteric site was designated as the ‘sugar 
monophosphate site’. However, its additional ability to act as an inhibitory allosteric site 
remained to be discovered. The only reported effector site that binds allosteric inhibitors of 
PYK was observed in M2PYK in human cancer cells, where Yuan et al. recently revealed that 
a single amino-acid site in M2PYK provides a competition mechanism to select between 
activators (serine and histidine) and inhibitors (phenylalanine, alanine, tryptophan, 
methionine, valine, and proline) acting as a rapid-response nutrient sensor to rebalance 
cellular metabolism[13]. 
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 Here, we searched for potential modulators of MtbPYK activity by screening a 
collection of sugar monophosphates (Fig.1). Interestingly, in contrast to the hexose 
monophosphate G6P, we found three structurally similar pentose monophosphates acted as 
inhibitors instead of activators of MtbPYK. Furthermore, a crystal structure showed that the 
pentose monophosphate ribose 5-phosphate (R5P) also binds to the sugar monophosphate 
site, which suggests that this single effector site provides a switch point selecting between 
inhibitor and activator to tightly control enzyme activity. Thermodynamic stability studies along 
with structural information indicate that the pentose monophosphate inhibits MtbPYK by 
destabilising the active state of the enzyme, while the activator G6P strongly stabilises the 
active conformation. This observation is further elaborated by molecular dynamic simulations 
showing that MtbPYK provides a conformational dynamics-driven allosteric mechanism for 
sensing either activator or inhibitor, thereby modifying the molecular dynamics of the enzyme. 
 An observed hypoxia-induced metabolic shift toward the PPP in the Mtb surrogate, 
Mycobacterium bovis BCG, is consistent with a pentose monophosphate-dependent inhibition 
of MtbPYK activity in response to low oxygen. Importantly, Anastasiou et al. discovered that, 
in cancer cells, the inhibition of human M2PYK through cysteine oxidation also enhanced the 
metabolic flux towards PPP as an antioxidant response[14]. However, unlike human M2PYK, 
MtbPYK is able to respond to multiple complex sugar monophosphate signals. It thereby 
provides the bacteria at the critical PEP-pyruvate-oxaloacetate node with a complex and rapid-
response allosteric mechanism to facilitate changes required to adapt to challenging 
environments. 
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Results 
 
Pentose monophosphates inhibit MtbPYK.  
We recently discovered a unique sugar monophosphate site on MtbPYK where binding of the 
hexose phosphate G6P allosterically activated the enzyme[12]. Structurally, the negatively-
charged phosphate of G6P was locked in place tightly by two salt bridges and three hydrogen 
bonds. This motivated us to ask if other sugar monophosphate metabolites with structures 
similar to G6P could be recognised by this effector site and function as enzyme modulators. 
To test this hypothesis, we first investigated the enzymic effects of a series of sugar 
monophosphates on MtbPYK at sub-saturating substrate concentrations (Fig. 1). We 
consistently observed a significant PYK activation (over 3-fold increase in activity) by adding 
G6P in agreement with our previous findings[12]. Interestingly, instead of discovering another 
new activator, we found three inhibitors: R5P, ribulose 5-phosphate (5RP) and xylulose 5-
phosphate (X5P). These pentose monophosphates from the pentose-phosphate pathway 
(PPP) share a highly similar chemical structure (Fig. 1a).  
 We then varied the concentrations of these three pentose monophosphates to 
investigate their role in MtbPYK enzyme inhibition (Table 1). All three pentose phosphate 
inhibitors show sub-millimolar inhibition (IC50 ~250 - 500 µM) that is comparable to the 
activation constant of G6P (Ka0.5 ~150 µM)[12], where R5P is the most potent inhibitor with 
IC50 = 251 ± 24 µM. To test whether they share the same effector site with G6P, we added 
G6P (0.14 mM) to the assay and observed decreased inhibitory activity by R5P (IC50 increased 
from 251 to 407 µM), which is consistent with pentose monophosphate competing with G6P 
for binding to the same effector site, as we demonstrate in subsequent structural studies. We 
further performed detailed kinetic studies of MtbPYK in the presence and absence of R5P, to 
evaluate the inhibitory mechanism. R5P decreased the apparent binding affinity of both 
substrates PEP and ADP, and slightly increased the cooperativity with respect to the substrate 
(h) (Table 1). In addition to changing the substrate binding affinity, R5P also decreased the 
maximum turnover number (kcat) of the chemical reaction. Taken together, these results 
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suggest that the pentose monophosphate is an uncompetitive inhibitor of MtbPYK, and 
indicate that this inhibitor recognises the substrate-bound conformation, thereby decreasing 
the progress of the enzymic reaction.  
 
The pentose monophosphate R5P binds at the G6P site.  
We next used X-ray crystallography to determine the location of the R5P binding site on 
MtbPYK. Efforts to co-crystallise R5P with MtbPYK or to soak R5P into unligated MtbPYK 
crystals were unsuccessful and we were unable to obtain high-quality crystals for X-ray 
diffraction, suggesting that the binding of R5P to the inactive T-state enzyme is unfavourable. 
We previously encountered a similar problem when we tried to solve the AMP- or G6P-bound 
structures without oxalate (OX), which mimics the substrate and locks the enzyme in its active 
R-state conformation[12]. By soaking the R-state MtbPYK crystal (active conformation in the 
presence of OX) with R5P, we were able to collect useful data and determined the structure 
at high resolution (Table 2). The R5P-bound MtbPYK structure comprises a complete tetramer 
in the asymmetric unit. All three domains (A-domain, B-domain and C-domain) of each subunit 
were well identified (Fig. 2a). The catalytic site is located in the cleft between A and B domains. 
The position of the B-domain is mainly regulated by the active-site ligands and its open-closed 
transition may play a role in the enzyme reaction mechanism[15]. Two effector sites are 
located ~40 Å away from the catalytic site (Fig. 2b). One effector site is the canonical allosteric 
site in the C-domain that binds AMP for activating MtbPYK. The other effector site, which 
involves domains A and C, binds the activator G6P as shown in our previous report[12] or the 
inhibitor R5P described in this study. Thus, this ‘sugar monophosphate site’ is a unique 
‘regulator-switching’ site that could either ‘switch on’ or ‘switch off’ the PYK activity by the 
binding of different modulators.  
 Clear electron density for the inhibitor R5P from each subunit is visible at the sugar 
monophosphate site (Fig. 2b, c). R5P is located in a similar position as the activator G6P (Fig. 
2c, d; Fig. S2). Interestingly, R5P was found to be in an open-chain form in the crystal structure, 
which is different from the sugar-ring form of G6P identified in previous structures. Briefly, R5P 
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is locked in place by salt bridges and hydrogen bonds (Fig. 2c, d; Fig. S2b). The phosphate 
of R5P forms salt bridges with two positively-charged residues, Arg382 and Arg385 (both on 
helix 2 of the C-domain, Cα2), and hydrogen bonds with the ‘monophosphate loop’ residues 
His345, Arg348, and Thr349. The pentose chain of R5P is hydrogen-bonded to Aα6 residues 
(Glu267, Asn268), the Cα2 residue (Arg382), and an additional water molecule. Note that 
Glu267 on Aα6 does not interact with G6P in the G6P-bound structure (Fig. 2c). Therefore, 
there is only a minor difference in binding mode between R5P and G6P at the sugar 
monophosphate site, which raises the question of why R5P is an inhibitor while G6P is an 
activator. We next explored the inhibitory mechanism by investigating the thermal stability and 
structural flexibility of MtbPYK in the presence of R5P. 
 
The pentose monophosphate R5P decreases the thermal stability and increases the 
dynamic movement of the B-domain.  
It has previously been shown that the binding of the active-site ligand oxalate triggers a 
conformational change (rigid-body rotation) of the MtbPYK tetramer toward its active R-state 
(PDB ID: 5WS8)[12] and slightly stabilises the enzyme in solution (ΔTm = 0.3 °C) (Fig. 3a). 
The activator G6P further increased the thermal stability of R-state MtbPYK by 1.7 °C, in 
agreement with our previous report[12]. In contrast to the thermal stabilisation effect by the 
substrate analogue and the activator, the binding of inhibitor R5P slightly decreased the 
melting temperature of MtbPYK (ΔTm = -1.3 °C). Interestingly, the product ATP, which normally 
decreases the dynamic movement of the B-domain[12,16], was able to partially reverse the 
effect of R5P (Fig. 3a), suggesting that the binding of R5P may be involved in the regulation 
of B-domain movement. 
 We next analysed the B-domain motions in different ligated states of MtbPYK. It is now 
well established that the lid-like B-domain has multiple conformations and that its closure 
movement towards the A-domain is initiated by the binding of active-site ligands including 
oxalate, PEP and ATP[15-17]. For example, oxalate binding causes the B-domains to rotate 
11° toward the A-domain compared with the unligated form (Fig. 3b; Table S1 and Fig. S3). 
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Also, additional interactions were formed to lock the B-domain in place when the B-domain 
was moving toward the A-domain (Table S2), leading to increased thermal stability[15]. 
Furthermore, we have shown that the B-domain regulator is not limited to ligands at the active 
site[12]. In MtbPYK, allosteric activators (AMP and G6P) could also trigger the closure 
movement of the B-domain by a further 7-9° rotation (Fig. 3b), even though the effector site is 
40 Å away from the B-domain. Importantly, comparing the B-domain position of the R5P-
bound structure with other MtbPYK structures, we found that the inhibitor R5P did not facilitate 
the closure movement of the B-domain (only 1° difference) even in the presence of the 
activator AMP (Fig. 3b; Fig. S3). This finding is consistent with the thermal stability result 
where no stability enhancement was found upon R5P binding. The open conformation of the 
B-domain is normally associated with much higher fluctuations to domain positions. 
 To gain further insight into R5P effects on MtbPYK, we examined the B-factor 
(temperature factor) parameter in X-ray crystallography, which has been widely used as an 
index of protein structural stability and residue flexibility[18]. Here we analysed the normalised 
B-factors from R5P-bound (PDB ID: 6ITO) and G6P-bound (PDB ID: 5WSC) MtbPYK 
structures. As shown in Fig. 3c, we observed higher B-factor values in the B-domains from the 
R5P-bound structure, which is consistent with the decrease in the thermal stability data (Fig. 
3a). Together, our results show that the binding of R5P to MtbPYK increases the dynamic 
movement of the B-domain, resulting in the observed higher crystallographic B-factor and 
contributing to the reduction of thermal stability. We next tested this model with molecular 
dynamics (MD) simulations on the MtbPYK tetramer to further investigate the role of R5P in 
MtbPYK dynamics.  
 
The molecular dynamics of MtbPYK.  
To gain new insight into the allostery of MtbPYK upon ligand binding, we performed three 
independent 300 ns MD simulations for each of three systems (oxalate, oxalate+G6P, and 
oxalate+R5P; see Materials and Methods), which is more rigorous compared with previous 
measurements where only a 150 ns MD simulation was carried out[12]. Firstly, the Cα root-
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mean-square-deviations (RMSDs) were calculated by superposing AC cores onto the starting 
crystal structure, to monitor the backbone fluctuations of MtbPYK. As shown in Fig. S4, the 
RMSD values of the AC cores are stabilised around 4 Å, indicating that the core protein 
structure is well preserved among all systems, while highly fluctuating RMSDs show that the 
B domains experience more dynamic movement. We then calculated the Cα root-mean-
square-fluctuation (RMSF) of each residue over all runs and averaged these values to 
compare the backbone flexibility in detail (Fig. 3d). Consistent with the RMSD results, only the 
B-domain region (residues 71–167) shows high dynamic movement, while the remainder of 
the subunit is relatively rigid. From Fig. 3e, it is clear that the R5P system is more dynamic 
(indicated by the red colour) than the G6P system, especially in the B-domains and the A-A 
and C-C interfaces. The binding of R5P also increases the dynamic movement of most of the 
sugar monophosphate loop compared with the binding of G6P, which might be propagated by 
the increased dynamics at the active site.  
 Both experimental data (Fig. 3a-c) and MD simulations (Fig. 3d) show that the binding 
of R5P increases the dynamic movement of the B-domain. Additionally, the closure of B-
domains toward the catalytic site, which stabilises B-domains in position by additional 
interactions, is an essential feature of the active state[15,16]. Thus, it is important to 
understand the movement of the B-domain in simulations. Here, we calculated the Cα-Cα 
distances of residues in either the monomer or the dimer (along the short axis of the tetramer) 
of MtbPYK, as a function of the presence of effector molecules (G6P and R5P). The 
differences are illustrated in Fig. S5. Within a monomer, G6P binding induces very small 
effects on the Cα-Cα distances. However, upon the binding of R5P, the B-domain moves away 
from the catalytic site (closer to residues 1-70 and 168-215 in the A-domain). Hence, a twisting 
of the B-domain is observed instead of a closure motion towards the catalytic site (Fig. S5a,b). 
For the dimer, in the presence of R5P, the B-domain in one monomer moves far away from 
the other monomer, indicating a more open conformation of the B-domains (Fig. S5c, d). Thus, 
although the allosteric site is ~40 Å away from the B-domain, binding of G6P or R5P there has 
obvious but distinctly different effects on both the dynamics and conformations of the B-
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domains. Together, the MD simulations agree with the preceding findings from thermal 
stability assays (Fig. 3a) and crystal structures (Fig. 3b and c), showing that the inhibitor R5P 
increases the protein structure flexibility and hinders the B-domain closure movement towards 
the catalytic site. 
 In addition, the three simulation systems show distinct binding stabilities of small 
molecules (oxalate and G6P/R5P) based on their heavy-atom RMSDs (Fig. S6 and S7). The 
smallest fluctuations of RMSDs were observed in the oxalate+G6P system for both oxalate 
and G6P, indicating their high binding stabilities. However, the binding of ligands in the 
oxalate+R5P system showed greater fluctuation. Therefore, the stable binding of G6P in the 
allosteric site enhances the binding of oxalate in the active site, while the relatively weak 
contact with R5P decreases its binding. Consistent with the biochemical results (Table 1; Fig. 
1b), G6P and R5P induce opposite allosteric effects propagating from the allosteric site to the 
active site. Compared to an open-chain conformation of R5P, the rigid ring of G6P markedly 
increases the steric hindrance, and reduces the degree of freedom of the small molecule. This 
might be the reason for the less ‘dynamic’ binding of G6P than R5P (Fig. S7). We next 
explored the community networks and allosteric pathways to further understand the inhibitory 
mechanism of R5P. 
 
Strengthened versus weakened intra- and inter-domain coupling through similar 
allosteric pathways.  
In MD simulations, a protein can be partitioned into communities based on physical contacts 
between residues and their positional correlation. Residues within communities form dense 
contacts, while forming sparse contacts between communities. Widely used in allosteric 
studies[19], community analysis is an effective way to reveal the pattern of motional coupling 
within a protein, so we used it here to further define the effects of G6P and R5P binding on 
MtbPYK. As shown in Fig. 4a-b, in the presence of G6P, residue coupling within MtbPYK is 
quite strong, leading to a dense and stable interaction network, which can promote efficient 
allosteric communication. Each monomer is partitioned into three communities upon G6P 
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binding, mainly corresponding to the A, B and C domains. However, when replacing G6P with 
R5P, domain A or community A is broken up into two communities, A and A' (Fig. 4c-d). 
Moreover, the inter-community connections are also weakened, indicating the weaker strength 
of coupling in the presence of R5P. Hence, a more localised and lower cooperative allosteric 
network is observed upon R5P binding. 
 To further explore the molecular basis of the opposite allosteric effects induced by G6P 
and R5P, potential allosteric pathways were identified between oxalate in the catalytic site and 
G6P/R5P in the sugar monophosphate site (referred to as OX-G6P and OX-R5P). A set of 
key residues with a high frequency of occurrence was identified from all the observed allosteric 
pathways. As illustrated in Fig. 4e-f, the key residues in OX-G6P and OX-R5P pathways are 
located in similar regions of the protein, sharing six residues of the top 10 of each: Ile216, 
Lys218, Asp244, Arg242, Glu267 and Asn268 (Fig. 4e). The OX-G6P pathway identified here 
is consistent with our previous simulation results[12]. Moreover, residues that occur the most 
often in the OX-G6P paths are more centralised than in the OX-R5P paths, which might be 
due to the higher flexibility of the R5P system. Indeed, the optimal path is found to be slightly 
shorter in the OX-G6P paths. Interestingly, the residues exclusive to OX-G6P path (Val232, 
Phe235 and Ala265) are hydrophobic residues, as well as the shared residue Ile216, so there 
is a consistent hydrophobic core in the middle of the OX-G6P pathway. Similar to the peptide 
that induces inter-domain allosteric communication in a peptidyl-prolyl cis/trans isomerase 
pin1[20], G6P might serve as a bridge linking the A and C domains, and hence its binding 
stabilises the conformation of the allosteric site, especially the allosteric loop (monophosphate 
loop). Although R5P binds at the same site, its high dynamics make its binding less stable 
than G6P, which might amplify the protein dynamics from the sugar monophosphate loop to 
both the A-A (through helices Aα6-Aα6′) and C-C interfaces (through Cα1) (Fig. 2a). 
Additionally, the hydrophobic core at the top of the allosteric site in the A-domain suggested 
by the pathway analysis might also be disturbed, which may further decrease oxalate binding 
in the catalytic site. 
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Positive versus negative allosteric regulation from the same site by fine-tuning of the 
conformational dynamics. 
Some reports have shown that tight binding of ligands can enhance residue coupling and 
further induce proteins to become more rigid and dense, especially around the binding site[19-
21]. This reduction in conformational dynamics has been observed in many positive allosteric 
modulations[19,20]. Interestingly, the less common negative allostery is often accompanied 
by the increase of conformational dynamics [21]. 
 As shown in Fig. 3 and 4, the two allosteric effectors in this study bind to an identical 
site, but induce distinct effects: G6P decreases protein flexibility and strengthens allosteric 
coupling, but R5P enhances the dynamics of the protein and weakens the internal 
communication. Based on our simulations, we speculate that, as the dominant allosteric 
pathways are similar for OX-G6P and OX-R5P, the opposite allosteric effects on the active 
site might be due to the opposing propagated signals of fine-tuned protein flexibility. In contrast 
to the conventional positive allosteric effectors shown in Fig. 4g(ii), the binding of allosteric 
inhibitors might disturb the intrinsic coupling and therefore propagate a reduced residue-
residue communication and increased protein conformational dynamics to the active site [Fig. 
4g(iii)]. This may in turn promote the higher rates of substrate dissociation and the decreased 
substrate affinity. With this complex allosteric mechanism driven by conformational dynamics, 
MtbPYK may sense different metabolites and react to stress-induced metabolic changes in M. 
tuberculosis cells as an adaptive response, as will be established in the next section. 
 
PYK facilitates the remodelling of carbon flux distribution towards the PPP in vivo. 
We next sought to place the complex allosteric mechanism of MtbPYK in the context of 
metabolic remodeling in mycobacteria. To understand the metabolic regulation and the carbon 
flux distribution around the PEP-pyruvate-oxaloacetate node in response to hypoxia, we 
subjected the well-characterized Mtb surrogate, M. bovis BCG[11,22,23], to hypoxic stress 
and applied chromatography-coupled tandem quadrupole mass spectrometry (LC-MS/MS) to 
quantify changes in the levels of relevant CCM intermediates. As shown in Fig. 5a, hypoxia 
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increased pentose-phosphate levels (R5P, 5RP and X5P) at 4 and 18 days (H4 and H18). 
After 3 days of reaeration (R3), pentose-phosphate levels shifted back to similar 
concentrations found in logarithmic growth. The finding that PPP intermediates accumulate is 
consistent with the work of Eoh and colleagues using a different hypoxia model[9]. We also 
observed an increase in histidine levels that correlated well with the R5P accumulation, which 
is reasonable since R5P is the core precursor for the synthesis of histidine. In contrast, most 
of the intermediates in the upstream steps of glycolysis were up-regulated, including G6P and 
fructose 6-phosphate (F6P), while the levels of downstream intermediates such as 
glyceraldehyde 3-phosphate (G3P) and PEP were reduced (Fig. 5a). Interestingly, only a 
small increase in the level of pyruvate was observed at the late stage of hypoxia (H18), 
suggesting that the flux toward the TCA cycle from pyruvate was relatively slow during 
hypoxia. In addition, hypoxia caused a sharp increase in malate in the TCA cycle and the 
reduction of acetyl-CoA, resulting from the up-regulation of the glyoxylate shunt for the 
demands of gluconeogenesis under hypoxic stress[24,25]. The glyoxylate shunt, bypassing 
the two carbon dioxide-generating steps of the TCA cycle, is known to be essential for using 
fatty acids as carbon sources under physiological conditions requiring gluconeogenesis[24-
26].  
 In contrast to the dramatic increase in AMP levels in nutrient deprivation[12], with AMP 
as a positive regulator of MtbPYK activity, hypoxia did not cause a notable change in levels of 
AMP (Fig. 5a), which points to a less important role for AMP regulation of MtbPYK activity in 
hypoxia. This suggests that the other two modulators, R5P and G6P, which show appreciable 
changes during hypoxia, are responsible for regulating MtbPYK activity in response to hypoxic 
stress.  
 
Discussion 
The sugar monophosphate site in MtbPYK provides the enzyme with a unique competitive 
allosteric mechanism – a conformational dynamics-driven allostery – that delivers a flexible 
‘regulator-switching’ system to decelerate or accelerate the reaction rate to meet the metabolic 
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demands during the cell stress response (Fig. 5b), depending on the relative concentrations 
of R5P (inhibitor) and G6P (activator) in cells. It has been reported that the intracellular 
concentrations of pentose monophosphates and G6P in bacteria (Escherichia coli) are in the 
millimolar range[27-30], further suggesting that changes of relative concentrations of pentose 
monophosphates and G6P could play a key role in PYK activity regulation at different growth 
stages of mycobacteria. The metabolic profiling results suggest that the carbon flux was 
directed to the PPP by the glyoxylate shunt and gluconeogenesis in response to the 
adaptation of mycobacteria to hypoxia. Thus, keeping the glycolytic PYK at a relatively low 
activity is necessary to prevent the reverse flow of carbon through the glycolytic pathway to 
the TCA cycle. In agreement with this model, we have observed the stress-induced increase 
of pentose phosphates that could serve as MtbPYK inhibitors, to presumably decelerate the 
carbon flow through PYK and subsequently change the carbon flux distribution by the PEP-
pyruvate-oxaloacetate node. It is noteworthy that hypoxia also induced an increase in the 
activator G6P simultaneously, further suggesting that the PYK activity is finely tuned by 
minute-to-minute changes in the relative concentrations of R5P and G6P. To our knowledge, 
this is the first demonstration that in bacteria, PYK uses one single allosteric site to 
accommodate opposing-effect modulators for facilitating metabolic reprograming. This 
regulatory mechanism has recently been reported for human M2PYK (namely ‘allostatic’ 
regulation) as a finely-balanced feed-back mechanism in cancer development[13]. 
 What are the physiological consequences in mycobacteria of up-regulating the 
glyoxylate shunt and increasing the carbon flux to the PPP during hypoxia? Exposure to 
hypoxia seems to result in a lower rate of glycolysis and a relatively higher glyoxylate shunt 
and gluconeogenesis activity that overcome glycolysis and reroute the flow of carbon to the 
PPP. The accumulation of metabolic intermediates during hypoxia was shown by Eoh and 
colleagues to be the result of an anticipatory metabolic regulatory response, required by M. 
tuberculosis for cell cycle re-entry[9].  
 Another potential physiological consequence of elevating the PPP flux is for redox 
balance (antioxidant response), which is also found in human cancer M2PYK through 
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posttranslational modification[14,31]. When bacterial cells encounter hypoxia, the redox 
potential will drop due to insufficient terminal electron acceptors for the respiratory chain. 
Thereafter, electron carriers of the chain become saturated and electrons ‘leaking’ from the 
chain may directly react with the small amounts of remaining oxygen to generate radicals 
(ROS) and cause damage[32-35]. NADPH (a major product of the PPP) is required to 
generate sufficient reducing potential for detoxification of ROS and to repair the damage[36]. 
Thus, in this work we have demonstrated that mammalian and bacterial PYKs have evolved 
alternative ways of regulating PPP for detoxification, where human M2PYK senses ROS[14] 
and mycobacterial PYK uses a unique competitive allosteric mechanism of sensing sugar 
monophosphates.  
  In addition, bypassing the carbon dioxide-generating steps of the TCA cycle where 
part of the cellular NADH pool is regenerated, could prevent the overloading of reduced 
electron carriers funnelled into respiration when oxygen is limited during hypoxia[24,32]. 
Therefore, this complex but sensitive allosteric scheme provides PYK with an efficient 
mechanism for helping M. tuberculosis to fine-tune metabolism and detoxification in response 
to hypoxia.  
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Materials and Methods 
 
Expression and purification of MtbPYK 
A codon-optimised MtbPYK gene (Bio Basic Inc.) was cloned into a pYUB28b-TEV vector (N-
terminal His6-tag followed by the TEV protease cleavage site) and the plasmid was used to 
transform chemically-competent E. coli BL21(DE3) cells (Novagen, Merck Millipore). MtbPYK 
protein was overexpressed and purified as described previously[12]. 
 
MtbPYK kinetics and inhibition assays 
PYK activity was measured at 25 °C by following NADH consumption as a decrease in 
absorbance at 340 nm using a microplate reader BioTek Synergy 4. To determine the 
inhibitory effect of pentose monophosphates on MtbPYK, enzyme activity and kinetics were 
determined as described previously[12] but in the presence of 2 mM inhibitor R5P. The data 
were analysed by the software Graphpad Prism 7.  The PYK inhibition assay was performed 
at 25 °C in 100 µl reaction mixtures containing 1x assay buffer (50 mM triethanolamine pH 
7.2, 100 mM KCl, 10 mM MgCl2), 0.2 mM ADP, 0.2 mM PEP, 0.5 mM NADH, 3.2 U L-lactate 
dehydrogenase (LDH) and 1.6 μg ml-1 MtbPYK. MtbPYK enzyme in 1x assay buffer was pre-
incubated with the inhibitor (R5P, 5RP or X5P) in a serial dilution at ambient temperature for 
10 min. The negative control mix was made up in an identical manner except 1x assay buffer 
was used in place of the inhibitor solution. To test the interplay between G6P and pentose 
phosphates on MtbPYK activity, we also carried out the inhibition assay for R5P in the 
presence of 0.14 mM G6P. The IC50 values for each inhibitor were estimated by expressing 
the reaction rate for each activity assay with a series of inhibitor concentrations as a 
percentage of the control assay and analysing the data using nonlinear regression fit in 
Graphpad Prism 7. All kinetics and inhibition results are summarised in Table 1. 
 
Thermal stability assay 
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The thermal stability analysis of MtbPYK was performed as described previously[12]. Briefly, 
4 μM MtbPYK enzyme was pre-incubated for 10 min with 5 mM of the test ligand(s) (oxalate, 
ATP, G6P, R5P) in a 96-well PCR plate (Bio-Rad) in assay buffer consisting of 50 mM 
triethanolamine pH 7.2, 100 mM KCl, 10 mM MgCl2. After incubation, 5x SYPRO Orange dye 
(Invitrogen) was added to make a final volume of 50 μl per reaction. The changes of 
fluorescence with increasing temperature ranging from 25 to 95 °C were monitored in the i-
Cycler iQ5 real-time PCR system (Bio-Rad). The temperature midpoint Tm for the protein-
unfolding transition was calculated using the Bio-Rad iQ5 software. 
 
Crystallisation and data collection 
Crystals of MtbPYK complexed with oxalate (OX) were grown by the vapour-diffusion method 
using the hanging-drop technique at 4 °C as described previously[12]. Briefly, crystals were 
grown in the solution consisting of 12% PEG 8000, 20% glycerol, 50 mM triethanolamine pH 
7.2, 100 mM KCl, 50 mM MgCl2 and 5 mM OX. To obtain the R5P-bound structure, MtbPYK-
OX crystals were soaked with a mixture of 5 mM each of AMP and R5P in 20% PEG 8000 
and 20% glycerol. Although we attempted to soak R5P into crystals of unligated MtbPYK (T-
state), the crystals did not diffract well after soaking. X-ray intensity data for the crystal of 
MtbPYK-OX/AMP/R5P were collected at the Swiss Light source (SLS, Switzerland). The 
dataset was from a single crystal flash-cooled in liquid nitrogen at 100 K. Data were processed 
with MOSFLM[37] and scaled with AIMLESS[38,39]. The data collection and processing 
statistics are summarised in Table 2. 
 
Structure determination 
The MtbPYK-OX/AMP/R5P structure was solved by molecular replacement using the program 
Phaser[40]. The initial search model for the molecular-replacement experiment was obtained 
from the published structure MtbPYK-OX/AMP/G6P (PDB ID: 5WSC). The structure was 
manually adjusted using Coot[41] followed by several cycles of restrained refinement in 
REFMAC[42]. Where appropriate, water molecules and ligands were added to the structure 
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and TLS refinement was applied at a later stage of refinement. The quality of the structures 
was assessed using the MOLPROBITY server[43], and the figures were generated using 
PyMOL[44]. The data processing and refinement statistics are summarised in Table 2. The 
structure factor and coordinates for MtbPYK-OX/AMP/R5P have been deposited in the RCSB 
Protein Data Bank as PDB entry 6ITO. 
 
Molecular dynamics simulations and community network analysis  
Three systems of MtbPYK were simulated in this study: OX, OX+G6P and OX+R5P. All 
models with Mg2+ in the active site were prepared based on the crystal structure of MtbPYK in 
complex with oxalate and G6P[12] (PDB ID: 5wsa), while the coordinates of R5P were taken 
from the complex with oxalate and R5P (PDB ID: 6ITO). All simulations were carried out using 
the AMBER 16 software[45] together with the AMBER14SB force field. The force field 
parameters for OX, R5P and G6P were generated using the general AMBER force field 
(GAFF) in the Antechamber suite. 
 Each complex was solvated in a cubic box with TIP3P waters[44], with an at least 10-
Å distance between the solute and the edge of the box. Sodium ions were added to neutralise 
the system. The whole system was first energy-minimised, with a series of position restraints 
on the solute (all heavy atoms, backbone atoms and ligands, C atoms and ligands). The 
simulation was continued for 300 ns at 1 bar (maintained by isotropic position scaling with a 
2-ps relaxation time) and 298.15 K (using the Langevin thermostat with a 2-ps-1 collision 
frequency). The SHAKE algorithm[46] was used to constrain all bonds involving hydrogens, 
allowing for a 2-fs timestep. Electrostatic interactions were treated by the particle mesh Ewald 
sum method[47], with a 8 Å cutoff for non-bonded interactions in direct space. Each system 
was simulated for three replicas. 
 The CPPTRAJ tool[48] was used for RMSD, RMSF and Cα-Cα distance calculations. 
The community network analysis was performed using the NetworkView plugin in VMD[48] 
with the default setting. The last 100 ns was used for analysis.  
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Mycobacterium bovis BCG culture and in vitro hypoxia model 
A well-defined and highly reproducible adaptation of the Wayne Model was used to induce 
hypoxic conditions in M. bovis BCG cultures[11,22,23]. Each replicate uses an inoculum 
prepared from a single colony picked from 7H11 agar plates and pre-cultured in 7H9 media in 
roller bottles, rotated at 50 rpm, for up to 14 days at 37 °C. Optical  densities at 600 nm (OD600) 
were monitored daily and cultures at mid-log phase (0.4 < OD600 < 0.8) were either harvested 
(Day 0) or diluted to an OD600 of 0.05 in Dubos medium (supplemented with Dubos Medium 
Albumin and Polysorbate 80). Polysorbate 80 was served as the carbon source for growth of 
mycobacteria. Non-replicating M. bovis BCG cultures were produced by subjecting bacilli to 
hypoxia caused by gradual oxygen consumption in sealed bottles, as previously 
described[11]. Briefly, aerobic cultures (780 ml) with an initial OD600 of 0.005 were expanded 
in glass bottles with a capacity of 1000 ml (Duran, Wertheim, Germany), achieving an optimal 
headspace ratio (HSR) as previously specified[49]. The sealed cultures were stirred gently at 
80 rpm for up to 18 days to allow the bacilli to enter into a non-replicating state on a self-
generated oxygen gradient. Subsequently, the select hypoxic cultures were reoxygenated by 
inoculating them into Erlenmeyer flasks containing fresh Dubos medium and shaking them on 
an orbital shaker at 140 rpm for up to 3 days. Oxygen depletion in these cultures was 
monitored by methylene blue coloration. Growth and survival were monitored by enumeration 
of colony-forming units (CFU) on Middlebrook 7H11 agar after a 4 week incubation at 37C. 
 
Metabolite extraction and metabolic profiling 
Metabolite extraction and targeted metabolomics analyses followed published reports with 
modifications[12,50]. Briefly, M. bovis BCG cell cultures were harvested at various times, 
rapidly quenched on ice and spun down. Cell pellets were resuspended in 
acetonitrile:methanol:water (2:2:1) and lysed mechanically with 0.1-mm silica beads by using 
QIAGEN TissueLyser II. The lysates were collected and evaporated to dryness in a vacuum 
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evaporator, and the dried extracts were redissolved in 100 µl of 98:2 water/methanol for LC-
MS/MS analysis. 
 The targeted LC-MS/MS analysis was performed with Agilent 1290 ultrahigh pressure 
liquid chromatography system coupled to a 6490 Triple Quadrupole mass spectrometer 
equipped with a dual-spray electrospray ionisation source (Agilent Technologies, Santa Clara, 
CA). Chromatographic separation of glycolysis intermediates was achieved by using a Rezex 
ROA-Organic Acid H+ (8%) column (2.1×100 mm, 3 µm; Phenomenex, Torrance, CA) and 
the compounds were eluted at 40 °C with an isocratic flow rate of 0.3 ml min-1 of 0.1% formic 
acid in water. Compounds were quantified in multiple-reaction monitoring (MRM) mode with 
the following transitions: m/z 259199 for glucose 6-phosphate (G6P), m/z 259169 for 
fructose 6-phosphate (F6P), m/z 8743.1 and m/z 8732.1 for pyruvate, m/z 16779 and 
m/z 16763 for phosphoenolpyruvic acid (PEP), m/z 16997 and m/z 16979 for 
glyceraldehyde 3-phosphate (G3P), m/z 22997 and m/z 22979 for the pentose-phosphate 
pool (ribulose 5-phosphate, ribose 5-phosphate and xylulose 5-phosphate), m/z 810428 and 
m/z 810303 for acetyl-CoA, and m/z 133115 and m/z 13371 for malic acid. AMP was 
analysed using an Agilent rapid resolution HT Zorbax SB-C18 column (2.150 mm, 1.8 mm; 
Agilent Technologies, Santa Clara, CA, USA) with the transition of m/z 348136. The gradient 
elution involved a mobile phase consisting of (A) 0.1% formic acid in water and (B) 0.1% formic 
acid in methanol. The initial condition was set at 2% B which was held for 3 min. A 2-min linear 
gradient to 95% B was applied, which was held for 3 min, then returned to starting conditions 
over 0.1 min. Histidine was analysed using an Atlantis HILIC column (2.1×100 mm, 1.7 µm; 
Waters, Eschborn, Germany) with the transition of m/z 348136. The gradient elution 
involved a mobile phase consisting of (A) 10 mM ammonium formate and 0.1% formic acid in 
water and (B) 0.1% formic acid in acetonitrile. The initial condition was set at 100% B for 2 
min, followed by a linear gradient to 80% B over 11 min and then down to 40% B over 1 min 
which was held for 5 min. Then the gradient returned to starting conditions over 1 min. The 
auto-sampler was cooled at 4 °C and an injection volume of 5 μl was used for all the analyses. 
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Electrospray ionisation was performed in both positive and negative ion modes with the 
following source parameters: drying gas temperature 300 °C with a flow of 10 l min-1, nebuliser 
gas pressure 40 psi, sheath gas temperature 350 °C with a flow of 11 l min-1, nozzle voltage 
500 V, and capillary voltage 4,000 V and 3,000 V for positive and negative mode, respectively. 
Data acquisition and processing were performed using MassHunter software (Agilent 
Technologies, US) and total peak area normalisation was performed to correct for variations 
in sample preparation. 
 Untargeted metabolomics were performed as previously described to obtain total peak 
area[51]. The redissolved dry extracts were analysed using an Agilent 1290 ultrahigh pressure 
liquid chromatography system equipped with a 6520 QTOF mass detector managed by a 
MassHunter workstation. The column used for the separation was an Agilent rapid resolution 
HT Zorbax SB-C18 column (2.1100 mm, 1.8 µm; Agilent Technologies, Santa Clara, CA, 
USA). The oven temperature was set at 45 °C. The gradient elution involved a mobile phase 
consisting of (A) 0.1% formic acid in water and (B) 0.1% formic acid in methanol. The initial 
condition was set at 5% B. A 7 min linear gradient to 70% B was applied, followed by a 12 min 
gradient to 100% B which was held for 3 min, then returned to starting conditions over 0.1 min. 
The flow rate was set at 0.4 ml min-1, and 5 ml of samples were injected. The electrospray 
ionisation mass spectra were acquired in positive ion mode. Mass data were collected 
between m/z 100 and 1000 at a rate of two scans per second. The ion spray voltage was set 
at 4,000 V, and the heated capillary temperature was maintained at 350°C. The drying gas 
and nebuliser nitrogen gas flow rates were 12.0 l min-1 and 50 psi, respectively. Two reference 
masses were continuously infused to the system to allow constant mass correction during the 
run: m/z 121.0509 (C5H4N4) and m/z 922.0098 (C18H18O6N3P3F24). Raw spectrometric data 
were analysed by MassHunter Qualitative Analysis software (Agilent Technologies, US) and 
the molecular features characterised by retention time (RT), chromatographic peak intensity 
and accurate mass, were obtained by using the Molecular Feature Extractor algorithm. The 
features were then analysed by MassHunter Mass Profiler Professional software (Agilent 
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Technologies, US). Only features with an intensity ≥ 20,000 counts (approximately three times 
the limit of detection of our LC-MS instrument), and found in at least 80% of the samples at 
the same sampling time point signal were kept for further processing. A tolerance window of 
0.15 min and 2 mDa was used for alignment of RT and m/z values. 
 
Accession numbers 
Coordinates and structure factors for MtbPYK-OX/AMP/R5P have been deposited in the 
Protein Data Bank under the accession code 6ITO.  
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Figure Legends 
 
 
Figure 1. Pentose phosphate metabolites inhibit enzyme activity of MtbPYK. (a) 
Structures of sugar monophosphate metabolites selected for activity testing against MtbPYK. 
(b) The regulation of MtbPYK activity by sugar monophosphates. The black and red asterisks 
indicate enzyme activation and inhibition, respectively. G6P was tested at 0.2 mM and other 
metabolites including PO43+ were tested at 1.25 mM. All data are mean ± SEM for N=3. 
 
Figure 2. The sugar monophosphate site regulates MtbPYK activity by binding to either 
hexose monophosphate (activation) or pentose monophosphates (inhibition). (a) 
Overview of crystal structure of MtbPYK tetramer. Each monomer comprises three domains 
shown in different colours. The polypeptide chains are shown as cartoons while ligands are 
shown as spheres. Helices that are essential in the allosteric pathway are highlighted in red 
for Cα1 and orange for Aα6-Aα6’. (b) A surface representation of the MtbPYK monomer (A-, 
B- and C-domains) highlighting the catalytic site and two effector sites. Ligands are shown as 
spheres. (c) Close-up view of the superposed sugar monophosphate site highlighting the 
similar ligand binding modes. Structures MtbPYK-OX/AMP/R5P (PDB ID: 6ITO) and MtbPYK-
OX/AMP/G6P (PDB ID: 5WSC) are superposed (C-α atoms fit) based on the AC-core (A and 
C domains) resulting in RMS fit of 0.23 Å. Ligand and interacting residues are shown as sticks 
while a water molecule is shown as a red sphere. R5P is highlighted with an unbiased Fo-Fc 
electron density map (blue) contoured at 3σ. Helices and the monophosphate loop that is 
involved in R5P binding are indicated. (d) A schematic representation showing the interatomic 
interactions at the sugar monophosphate site of the R5P-bound structure. The activator G6P 
is superposed to R5P to compare the binding mode. 
 
Figure 3. R5P regulates the dynamic movement of the B-domain. (a) Thermal stability 
assay results show that R5P destabilises MtbPYK while the activator G6P stabilises the 
enzyme in the R-state (OX-bound). Adding ATP reduces the dynamic movement of the B-
domain and thus increases thermal stability of the enzyme. The melting temperature Tm values 
(oC) are shown above the bars. All data are mean ± SEM for N=3. (b) B-domain motions in 
different ligated states of MtbPYK. Subunits from six MtbPYK structures (chain D in each 
structure) are superposed based on the AC-core (A and C domains) thereby showing the 
movements (indicated by an arrow) of the B-domains: T-state MtbPYK (PDB ID: 5WRP), 
MtbPYK-OX (PDB ID: 5WS8), MtbPYK-OX/AMP (PDB ID: 5WS9), MtbPYK-OX/G6P (PDB ID: 
5WSA), MtbPYK-OX/AMP/G6P (PDB ID: 5WSC), MtbPYK-OX/AMP/R5P (PDB ID: 6ITO). AC-
cores are shown as cartoons while the B domains are represented by ribbons. The rotation 
angles of the B-domain relative to the T-state structure are indicated. The details of the B-
domain positions are described in Table S1 and Fig. S3. (c) B-factor analysis of MtbPYK 
tetramers indicates that the binding to R5P reduces the stability of the B-domain. The 
normalised B-factors (Å2) of Cα atoms in the R5P-bound structure (light blue; PDB ID: 6ITO) 
and G6P-bound structure (black; PDB ID: 5WSC) are compared in the top panel. The bottom 
panel shows their difference in MtbPYK: (normalised B-factors of Cα atoms in R5P-bound 
structure) - (normalised B-factors of Cα atoms in the G6P-bound structure). B-domains from 
the four chains (A, B, C and D) in a tetramer are shaded in light yellow. (d) The backbone 
fluctuations in the absence and presence of allosteric ligands during the last 100 ns in MD 
simulation. The Cα RMSFs of individual residues in each system were plotted. (e) Differences 
in RMSFs of the R5P-bound form from those of the G6P-bound form are coloured on the 
protein structure. Red and blue colours represent higher and lower flexibilities, respectively. 
A-A and C-C interfaces are indicated by dashed lines. B-domains are indicated by arrows. 
 
Figure 4. Community and allosteric pathway analysis. (a,b) Communities of the G6P-
bound MtbPYK system. (c,d) Communities of the R5P-bound MtbPYK system. On the top, the 
communities represented by circles are connected by inter-community edges, and the edge 
width is proportional to the cumulative betweenness. The corresponding structures (bottom) 
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are shown in cartoon coloured by community. (e) Key residues involved in the allosteric 
pathways between the catalytic site and the sugar monophosphate site. The top 10 residues 
in each pathway are shown as spheres, and the protein is drawn in ribbon, with A, B and C 
domains in silver, blue and light purple, respectively. The shared portion of the key residues 
is coloured in ochre. Residues unique in OX-G6P pathways are in red, and those unique in 
OX-R5P pathways are in green. (f) The frequency of residues involved all recognized 
pathways. Top residues identified from the pathway analysis are indicated. (g) Illustration of 
the positive (ii) and negative (iii) allosteric regulation mechanisms of MtbPYK by G6P and 
R5P, respectively. Schematic representations of MtbPYK tetramer (i) and monomer are 
shown, where domains, ligands and loops are indicated. The allosteric effects propagate from 
the allosteric site to the catalytic centre through pathways. The changes in dynamics and the 
allosteric coupling are indicated by arrows and coloured in either blue or red. G6P represents 
tight binding ligands in positive allosteric regulation (blue), while R5P corresponds to relatively 
weaker binding of allosteric inhibitors (red). 
 
Figure 5. A conformational dynamics-driven allostery regulates pyruvate kinase activity 
to fine-tune metabolism and control redox homeostasis in M. tuberculosis. a, Schematic 
illustration of glycolysis, pentose-phosphate pathway, TCA cycle, glyoxylate shunt, and 
histidine synthesis in M. bovis BCG. The bigger arrow indicates the increased flux during 
hypoxia. Histograms of metabolic changes at H4, H18 and R3 against Log in M. bovis hypoxia 
model; abundance data represent mean ± SEM, N = 3. Polysorbate 80 served as a fatty acid 
surrogate in this hypoxia model. b, A three-dimensional (3D) representation of MtbPYK with 
a ‘regulator-switching’ system for differential transmission of allosteric inhibition and activation 
signals. One subunit of MtbPYK tetramer is highlighted showing the catalytic site comprised 
of the A-domain (beige) and B-domain (blue box at top), and C-domain allosteric site (light 
purple at bottom). The metabolites Pentose-P (ribose-5-P, ribulose-5-P, xylulose-5-P), 
glucose-6-P (G6P) and AMP are shown as gears coloured in blue, magenta and purple, 
respectively. The sugar monophosphate site in the C-domain is represented by the 
transparent ‘effector’ gear that switches between inhibition by Pentose-P and activation by 
G6P. These regulatory signals are transmitted (dashed lines) to the catalytic site (gear in A-
domain). When AMP levels do not change, the ‘effector’ engages the A-domain to regulate 
catalytic inhibition and activation by Pentose-P and G6P, respectively. 
